Managed Healthcare Executive March 20, 2024
Lenmeldy is the first approved gene therapy to treat children with juvenile metachromatic leukodystrophy, a life-threatening inherited disease of the body’s metabolic system.
Orchard Therapeutics has set the wholesale acquisition cost of its newly approved gene therapy, Lenmeldy (atidarsagene autotemcel), at $4.25 million for the one-time treatment. Company officials in a press release said this price reflects its clinical, economic and societal value.
The FDA had announced the approval of Lenmeldy on Monday. It is the first approved gene therapy to treat children with juvenile metachromatic leukodystrophy (MLD), a rare and life-threatening inherited disease of the body’s metabolic system.
“We are confident in the potential long-term clinical outcomes of Lenmeldy and will continue to work with public and private payers...
Today's Sponsors
Today's Sponsor